Favorable outcome of neonatal cerebrospinal fluid shunt-associated Candida meningitis with caspofungin.

scientific article published on 25 February 2013

Favorable outcome of neonatal cerebrospinal fluid shunt-associated Candida meningitis with caspofungin. is …
instance of (P31):
case reportQ2782326
scholarly articleQ13442814

External links are
P356DOI10.1128/AAC.02085-12
P8608Fatcat IDrelease_djv3c2dzivfpzhbmkiqpb5lf7m
P932PMC publication ID3632945
P698PubMed publication ID23439643

P50authorRoger J BrüggemannQ88523388
Viola ChristmannQ57564453
Paul E. VerweijQ70514014
Adilia WarrisQ73423823
P2093author name stringJop Jans
P2860cites workIn vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated CandidiasisQ34150935
Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patientsQ34932330
Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersionQ35065709
Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.Q35689202
Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.Q37115709
Pharmacokinetics and safety of caspofungin in older infants and toddlersQ37144851
The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonatesQ37320912
Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilmsQ41912237
In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus speciesQ42738793
Treatment of meningeal coccidioidomycosis with caspofunginQ44931223
Caspofungin therapy of neonates with invasive candidiasisQ45207584
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeastsQ46812076
Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 monthsQ47354614
EUCAST technical note on anidulafunginQ47577071
A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid.Q51185856
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectmeningitisQ48143
cerebrospinal fluidQ54196
P304page(s)2391-2393
P577publication date2013-02-25
P1433published inAntimicrobial Agents and ChemotherapyQ578004
P1476titleFavorable outcome of neonatal cerebrospinal fluid shunt-associated Candida meningitis with caspofungin
P478volume57

Reverse relations

cites work (P2860)
Q57476185Advances in the Treatment of Mycoses in Pediatric Patients
Q38462784Impact of special patient populations on the pharmacokinetics of echinocandins.
Q38193337Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.
Q41929675Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children.

Search more.